In theory, if tolerable, a dual combination of immune strategies in the consolidation setting with complementary mechanisms of action may also overcome resistance to anti-PD-(L)-1 antibodies and further enhance the benefits of immunotherapy in LA-NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.